pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Apr 30·2 min read
save

STAT+: Hinge has a new FDA-cleared migraine device

In this edition of STAT Health Tech: FDA's plan to use AI to speed up trials, Hinge's new migraine device, and boosting cancer screening with texts.

Apr 30, 2026·read at STAT ↗

STAT PlusNewsletterHealth Tech Newsletter Hinge has a new FDA-cleared migraine device You’re reading the web edition of STAT’s Health Tech newsletter Manage alerts for this article Email this article Share this article By Mario AguilarApril 30, 2026 Health Tech Correspondent Mario Aguilar[email protected]Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech’s promise. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter.

You can reach Mario on Signal at mariojoze.13. You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Good morning health tech readers!Advertisement Today, updates from large virtual care companies. Plus: A low-tech way to boost cancer screenings. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In health tech, Health Tech Newsletter, STAT+ Submit a correction requestReprints Mario Aguilar Health Tech Correspondent Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.

His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech’s promise. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.

STAT+ Newsletter A hitchhiker's guide to the health care AI galaxy Recommended Health Tech Newsletter April 28, 2026 STAT Plus: Google’s clinical director on AI challenges Health Tech Newsletter April 23, 2026 STAT Plus: AMA calls for regulatory crackdown on chatbots, wellness AI Advertisement Health Tech Newsletter April 21, 2026 STAT Plus: Kennedy hints at coming breakthrough device announcement Health Tech Newsletter April 16, 2026 STAT Plus: Medicare may nix breakthrough device payment pathway Health Tech Newsletter April 14, 2026 STAT Plus: Hospitals offer chatbots to fight off ChatGPT Subscriber Picks

source

Reporting by STAT.

read at STAT ↗
441 words · retrieved Apr 30
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Oncology2

related stories

  • Apr 27Erasca reports RAS cancer drug data after legal threat from RevolutionEndpoints
  • Apr 27Revolution Medicines threatens to sue Erasca over patent, efficacy claimsEndpoints
  • Apr 27Lilly to buy startup Ajax in bid for a better JAK drugBioPharma Dive
  • Apr 27STAT+: Astellas retries XLMTM gene therapy after deathsSTAT
  • Apr 27Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitorEndpoints